Enterovirus infections following T-cell depleted allogeneic transplants in adults

Chakrabarti, Suparno; Osman, Husam; Collingham, Kathryn E.; Fegan, Christopher; Milligan, Donald

doi:10.1038/sj.bmt.1704359

Cited by 17 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infections are a frequent complication of immunosuppression and T cell depleting regimens. [41][42][43][44] Three of the four deaths in this study were due to infectious complications. Both bacterial infections that resulted in mortality were detected just prior to transplant, a complication previously described.…”

Section: Campath-1h For Nonmalignant Disease Transplants S Shenoy Et Almentioning

confidence: 99%

“…[37][38][39] This delay in T and B cell immune reconstitution which translates into late onset infections resulting in morbidity and mortality, was not seen in our transplant recipients who had few infectious complications after the first 3 months. 37,40,41 The timing and dosing schedule we used for Campath-1H were different from previous studies. The maximum total dose of Campath-1H used was 48 mg even in adult recipients, in contrast to 100 mg previously used in vivo.…”

Section: Campath-1h For Nonmalignant Disease Transplants S Shenoy Et Almentioning

confidence: 99%

See 1 more Smart Citation

A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders

Shenoy

Grossman

DiPersio

et al. 2004

Bone Marrow Transplant

129

110

View full text Add to dashboard Cite

Summary:Bone marrow transplantation (BMT) benefits nonmalignant diseases but is limited by regimen-related toxicity, graft-versus-host disease (GVHD), donor availability, and graft rejection (GR). To overcome some of these barriers, we developed a new conditioning strategy for these patients. In total, 16 patients received Campath-1H (33/ 48 mg; days À21 to À19), fludarabine (150 mg/m 2 ; days À8 to À4), melphalan (140/70 mg/m 2 ; day À3), and transplant using related/unrelated stem cells. GVHD prophylaxis included cyclosporine/methylprednisolone for cord cells. Other recipients also received methotrexate. Risk factors for GR included multiple transfusions (6), low stem cell numbers (1), and immunologic/ metabolic disorders (3).

show abstract

Section: Campath-1h For Nonmalignant Disease Transplants S Shenoy Et Almentioning

confidence: 99%

Section: Campath-1h For Nonmalignant Disease Transplants S Shenoy Et Almentioning

confidence: 99%

A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders

Shenoy

Grossman

DiPersio

et al. 2004

Bone Marrow Transplant

129

110

View full text Add to dashboard Cite

show abstract

“…with hematological malignancies and stem cell transplant recipients [11,[12][13][14][15]. As far as we know, this is the largest series reviewed of respiratory infections caused by HRV and HEV in the setting of immunocompromised patients with hematological malignancies.…”

Section: Discussionmentioning

confidence: 98%

“…Sixtyseven serotypes of HEV have been described, causing a wide range of clinical symptoms [10]. There are several reports where HEV are implicated in fatal complications after HSCT [11][12][13]. Chakrabarti et al studied the incidence and relevance of HEV infections in T-cell depleted transplants and found an unrelated donor graft to be the only significant risk factor [11].…”

Section: Introductionmentioning

confidence: 99%

“…There are several reports where HEV are implicated in fatal complications after HSCT [11][12][13]. Chakrabarti et al studied the incidence and relevance of HEV infections in T-cell depleted transplants and found an unrelated donor graft to be the only significant risk factor [11]. On the other hand, HRV is the most frequent cause of the common cold and is considered to replicate principally within the upper respiratory tract (URT).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies

et al. 2007

View full text Add to dashboard Cite

The impact of human enterovirus (HEV) and human rhinovirus (HRV) respiratory tract infections in adult patients with hematological malignancies has been infrequently reported. We retrospectively studied 31 patients with an upper or lower respiratory tract infection (URTI/LRTI) by HEV (n = 18) or HRV (n = 15). At onset, a LRTI was present in 6 (33%) and 2 (13%) episodes of HEV and HRV infections, respectively, with or without an URTI. Progression to LRTI (pneumonia) from prior URTI was seen in 1 (6%) and 2 (13%) HEV and HRV infections, respectively. The presence of lymphocytopenia (< <0.5 3 10 9 /l) was higher in LRTI by HEV: 4/ 5 (80%) versus 2/10 (20%) by HRV. Eight of 18 (44%) patients with immunosuppression versus 3/14 (21%) patients with no immunosuppression at the onset of respiratory infection developed a LRTI. Thirteen per cent of patients had associated respiratory infections from bacteria, aspergillus, or CMV. Pulmonary aspergillosis was diagnosed in 20% of HRV infections. Three of 11 patients (27%) with a LRTI died, but pulmonary copathogens were also involved in all cases. In conclusion, HEV and HRV can be associated with LRTI in immunocompromised patients, although their direct impact on mortality is uncertain. Am. J. Hematol. 82:807-811, 2007. V

show abstract

Enterovirus Infection in Immunocompromised Hosts

Schaenman

Baden

et al. 2019

Principles and Practice of Transplant Infectious Diseases

View full text Add to dashboard Cite

Enterovirus infections following T-cell depleted allogeneic transplants in adults

Cited by 17 publications

References 29 publications

A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders

A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders

Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies

Enterovirus Infection in Immunocompromised Hosts

Contact Info

Product

Resources

About